Shares of Biogen Idec (NASDAQ:BIIB) were initially flat when the company reported earnings last week but have seen a sell-off since then. The slump in the stock, however, was partially due to an overall downward trend in biotech at the moment, and in this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass note that they actually see a lot to like here.
Revenue for the company beat estimates by about 7% because of the upsides from both Tecfidera and Avonex, and although earnings per share did ultimately miss by $0.08 per share, David says he sees that as mostly an expectations game. The company mentioned doing $200 million in deals this year, but its deals with Eisai and Sangamo that fell early this year and totaled nearly $150 million meant that the $200 million figure didn't spread evenly throughout the year, and affected Wall Street's expectations.
In the video, David and Michael go over the numbers and Biogen's impressive pipeline, and tell investors why this sell-off may be a case of market overreaction.
David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.